RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States
Nabhan, C., Zhou, X., Day, B.-M., Dawson, K., Zelenetz, A. D., Friedberg, J. W., Cerhan, J. R., Link, B. K., & Flowers, C. R. (2016). Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. American Journal of Hematology, 91(8), 770-775. https://doi.org/10.1002/ajh.24401
We aimed to comprehensively study sex differences in disease and patients' characteristics, treatment and outcomes in patients with follicular lymphoma (FL) in the United States (USA) utilizing the National LymphoCare Study registry (2004-2014). Among evaluable males (n=1277) and females (n=1375) with FL, females less commonly received anthracyclines and were more likely to receive rituximab monotherapy. Overall response rates were comparable between sex groups. With a median follow-up of 8.1 years, male sex emerged as an adverse factor for PFS (HR, 0.84, 95% CI, 0.72-0.97). Lymphoma-related mortality (HR, 0.46; 0.23-0.93) and overall survival (HR, 0.63; 0.41-0.97) favored females aged 60 years. There are subtle differences in outcomes between male and female FL patients diagnosed and treated in the contemporary era. These data represent the largest prospective analysis of FL patients in the USA based on sex and can aid design of clinical trials for this disease. Am. J. Hematol. 91:770-775, 2016. (c) 2016 Wiley Periodicals, Inc.